Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →What's hot!
View all perspectives
What's Hot
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented in London at the EULAR 2026 Congress.
Watch video →
Antoni Chan MD (Prof) synovialjoints
6 days 19 hours ago
103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up.
Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64
Nelly ZIADE 🍀 Nellziade
6 days 19 hours ago
How many patients from real life fulfill the inclusion criteria of clinical trials?
Not so many ⬇️
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/U6vlzOYS4X
Mrinalini Dey DrMiniDey
6 days 19 hours ago
#OP0349 Higher pericoronary fat attenuation (PCATa) in RA vs controls, with PCATa assoc with coronary plaque burden only in RA. Suggests coronary inflammation may precede overt plaque changes; supports PCATa as potential CV inflammation biomarker in RA. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey
6 days 19 hours ago
#OP0348 CT-based analysis in RA showed increased subcutaneous and intermuscular fat plus reduced muscle quality versus non-RA comparators, despite similar BMI-adjusted muscle area and visceral fat. Highlights “hidden” adverse body composition changes in RA. #EULAR2026 @RheumNow
Antoni Chan MD (Prof) synovialjoints
6 days 19 hours ago
Optical spectral transmission (OST) a non-invasive light-based scan of hand joints monitored inflammatory arthritis activity over time in 60 patients, 1,312 joints.
OST correlated with DAS28-CRP (r=0.500, p<0.001), swollen joint count (r=0.535, p<0.001), and AUC 0.781 for https://t.co/AHrybe1Rrn
Mrinalini Dey DrMiniDey
6 days 19 hours ago
#OP0347 In CCP-positive at-risk individuals with MSK symptoms, MRI-detected hand tenosynovitis independently predicted progression to IA (HR 1.21), alongside US positivity (HR 2.77). MRI added little predictive value in patients with negative US findings. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey
6 days 19 hours ago
#OP0346 In clinically suspect arthralgia, US missed ~3/4 cases of tenosynovitis detected by modified Dixon MRI. Compared to mDixon MRI, US sensitivity was 23%; specificity remained 100%. Potential for fast non-contrast MRI in early RA risk stratification. #EULAR2026 @RheumNow https://t.co/h3FhLEC2je
Antoni Chan MD (Prof) synovialjoints
6 days 19 hours ago
The RADIAL study integrates point-of-care ultrasound into the diagnostic work-up for suspected inflammatory arthritis. 601 patients, 6 diagnoses, 1 algorithm.
Result: NPV above 90% for most diagnoses. The Double Contour sign for gout: OR 52.66. PPV for RA: 0.85.
Ultrasound at
Mrinalini Dey DrMiniDey
6 days 19 hours ago
#OP0345 Lung US outperformed clinical risk scores for detecting RA-assoc ILD, incl in asymptomatic patients. Compared with HRCT, LUS achieved 95.4% sensitivity & 77.7% specificity. Combining LUS with risk scores incr sensitivity to 100% for ILD detection. #EULAR2026 @RheumNow
Nelly ZIADE 🍀 Nellziade
6 days 19 hours ago
Live vaccinations in infants antenatally exposed to bDMARDs
⬇️⬇️
#WIN session @lauraandreoli80
#EULAR2026 @RheumNow https://t.co/84MCwb2fbT
sheila RHEUMarampa
6 days 19 hours ago
Dr. Laura Andreoli shares this slide showing the impact of rheumatic disease in reproductive health as described by Dr. MOstensen.
These interplay of factors affect patients and should be taken into consideration when managing fertility & pregnancy.
@RheumNow #EULAR2026 https://t.co/fB9kuD4kXo
Antoni Chan MD (Prof) synovialjoints
6 days 19 hours ago
Double targeted therapy in refractory SpA/PsA.
76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics.
Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit.
ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX
Mrinalini Dey DrMiniDey
6 days 19 hours ago
Starting the “Imaging innovation in RA” session with #OP0343: Singapore investigators developed an AI-based thermography model to detect RA wrist inflammation using thermal hand images, achieving an AUC of 0.87 against ultrasound power doppler as reference. #EULAR2026 @RheumNow https://t.co/2v39E6VOWB
sheila RHEUMarampa
6 days 19 hours ago
10yr ffup data on 49pts from the OG CRESPA study (GOL vs PBO in very early pSpA):
81.6% (40/49) were in clinical remission
15 pts on drug-free remission
21 pts w/remission on meds still on GOL, no unSSAEs
Early aggressive tx is key!
AbsPOS0931 @RheumNow #EULAR2026 https://t.co/HrTF5XtAZt
sheila RHEUMarampa
6 days 19 hours ago
This study describes the SIJ differences in axSpA vs. non-axSpA pts with CBP
axSpA: BME w/ widespread distribution & inflamm⬇️ over time
non-axSpA: BME rare or limited only to ventral & middle superior sacrum
Findings may improve MRI ID of axSpa
AbsPOS0193 @RheumNow #EULAR2026 https://t.co/7eiHQOOIWs
